Effect of Including Cancer Mortality on the Cost-Effectiveness of Aspirin for Primary Prevention in Men

Pignone, Michael; Earnshaw, Stephanie; McDade, Cheryl; Pletcher, Mark
November 2013
JGIM: Journal of General Internal Medicine;Nov2013, Vol. 28 Issue 11, p1483
Academic Journal
BACKGROUND: Recent data suggest that aspirin may be effective for reducing cancer mortality. OBJECTIVE: To examine whether including a cancer mortality-reducing effect influences which men would benefit from aspirin for primary prevention. DESIGN: We modified our existing Markov model that examines the effects of aspirin among middle-aged men with no previous history of cardiovascular disease or diabetes. For our base case scenario of 45-year-old men, we examined costs and life-years for men taking aspirin for 10 years compared with men who were not taking aspirin over those 10 years; after 10 years, we equalized treatment and followed the cohort until death. We compared our results depending on whether or not we included a 22 % relative reduction in cancer mortality, based on a recent meta-analysis. We discounted costs and benefits at 3 % and employed a third party payer perspective. MAIN MEASURE: Cost per quality-adjusted life year (QALY) gained. KEY RESULTS: When no effect on cancer mortality was included, aspirin had a cost per QALY gained of $22,492 at 5 % 10-year coronary heart disease (CHD) risk; at 2.5 % risk or below, no treatment was favored. When we included a reduction in cancer mortality, aspirin became cost-effective for men at 2.5 % risk as well (cost per QALY, $43,342). Results were somewhat sensitive to utility of taking aspirin daily; risk of death after myocardial infarction; and effects of aspirin on stroke, myocardial infarction, and sudden death. However, aspirin remained cost-saving or cost-effective (< $50,000 per QALY) in probabilistic analyses (59 % with no cancer effect included; 96 % with cancer effect) for men at 5 % risk. CONCLUSIONS: Including an effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. If such an effect is real, many middle-aged men at low cardiovascular risk would become candidates for regular aspirin use.


Related Articles

  • BMD test/alendronate combo cost effective for PCa patients on ADT.  // Urology Times;Jul2010, Vol. 38 Issue 8, p50 

    The article discusses the cost effectiveness of bone mineral density mixed with alendronate for prostate cancer patients who undergoes androgen deprivation therapy.

  • Clopidogrel considered "value for money" in Greece.  // PharmacoEconomics & Outcomes News;9/15/2012, Issue 662, p4 

    The article discusses the results of a study which shows the cost effectiveness of clopidogrel over aspirin, referencing the research "Clopidogrel versus aspirin in patients with atherothrombosis: A CAPRIE-based cost-effectiveness model for Greece," by G. Kourlaba and colleagues.

  • Low-dose aspirin cost saving in CVD.  // PharmacoEconomics & Outcomes News;7/11/2009, Issue 582, p4 

    The article focuses on a study presented at the 69th Annual Scientific Sessions of the American Diabetes Association which showed that low-dose aspirin in patients with or without diabetes mellitus is cost saving for patients at a 4% cardiovascular disease (CVD) risk or higher in the U.S. The...

  • Cost-Effectiveness of Aspirin Use Among Persons With Newly Diagnosed Type 2 Diabetes. Li, Rui; Zhang, Ping; Barker, Lawrence E.; Hoerger, Thomas J. // Diabetes Care;Jun2010, Vol. 33 Issue 6, p1193 

    OBJECTIVE -- To assess the long-term cost-effectiveness of aspirin use among adults aged ≤ 40 years with newly diagnosed type 2 diabetes. RESEARCH DESIGN AND METHODS--We used a validated cost-effectiveness model of type 2 diabetes to assess the lifetime health and cost consequences of...

  • Picotamide likely cost effective vs aspirin for preventing CV events.  // PharmacoEconomics & Outcomes News;1/27/2007, Issue 520, p8 

    The article reports on the cost effectiveness of picotamide in preventing cardiovascular events among patient with diabetes and peripheral arterial disease. According to study conducted by researchers from Italy, they created a Markov model to determine the cost effectiveness of lifetime...

  • Gemcitabine regimen cost effective in cervical cancer.  // PharmacoEconomics & Outcomes News;9/15/2012, Issue 662, p7 

    The article discusses the results of a study which shows the cost effectiveness of gemcitabine treatment in addition to cisplatin chemoradiation in patients with locally advanced cervical cancer, referencing a research published in the August 2012 issue of the "Gynecologic Oncology" journal.

  • ProsVue-guided therapy economically attractive in the US?  // PharmacoEconomics & Outcomes News;Aug2014, Vol. 710 Issue 1, p22 

    The article discusses a research that shows the economic value of the potential cost effectiveness of ProsVue-guided radiotherapy for patients with high-risk characteristics among prostate cancer patients at intermediate risk for recurrence and among those who experience toxicities to radiotherapy.

  • Prostate cancer chemoprevention: value rises with risk.  // PharmacoEconomics & Outcomes News;6/26/2010, Issue 606, p7 

    The article discusses research on the cost effectiveness of 5-alpha reductase inhibitors in preventing prostate cancer in multiple patient populations, referencing a study by S. R. Earnshaw and colleagues published in the June 2010 issue of "PharmacoEconomics."

  • Trastuzumab cost effectiveness in the UK updated.  // PharmacoEconomics & Outcomes News;5/28/2011, Issue 629, p5 

    The article discusses research on the cost effectiveness of trastuzumab administration in patients with early breast cancer in Great Britain, referencing a study by P.S. Hall and colleagues published in "PharmacoEconomics."


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics